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Abstract
Objective—Clinical response to antipsychotic drug treatment is highly variable, yet prognostic
biomarkers are lacking. The authors recently demonstrated that successful antipsychotic drug
treatment alters resting-state functional connectivity of the striatum. The goal of the present study
was to test whether intrinsic striatal connectivity patterns provide prognostic information and can
serve as a potential biomarker of treatment response to antipsychotic drugs.

Author Manuscript

Method—The authors used resting-state functional MRI (fMRI) to develop a prognostic index in
a discovery cohort of 41 first-episode schizophrenia patients, then tested this index in an
independent cohort of 40 newly hospitalized chronic patients with acute psychosis. In the
discovery cohort, patients underwent resting-state fMRI scanning at the initiation of randomized
controlled treatment with a second-generation antipsychotic. Whole-brain functional connectivity
maps were generated for each subject from striatal seed regions. A stringent measure of clinical
response was calculated that required sustained improvement over two consecutive study visits.
Clinical response was entered into a survival analysis, and Cox regression was applied to the
functional connectivity data. A striatal connectivity index was created, comprising functional
connections of the striatum that predicted treatment response. This striatal connectivity index was
tested on a generalizability cohort of patients with psychotic disorders who were hospitalized for
an acute psychotic episode.

Author Manuscript

Results—A total of 91 regions functionally connected with the striatum provided significant
prognostic information. Connectivity in these regions was used to create a baseline striatal
connectivity index that predicted response to antipsychotic treatment with high sensitivity and
specificity in both the discovery and generalizability cohorts.

Address correspondence to Dr. Malhotra (amalhotra@nshs.edu).
The first two and last two authors contributed equally to this study.
Presented at the 53rd annual meeting of the American College of Neuropsychopharmacology, Phoenix, Dec. 7–11, 2014, and at the
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Conclusions—These results provide evidence that individual differences in striatal functional
connectivity predict response to antipsychotic drug treatment in acutely psychotic patients. With
further development, this has the potential to serve as a prognostic biomarker with clinical utility
and to reduce the overall burden associated with psychotic illnesses.
Chronic psychotic disorders are estimated to occur in more than 3% of the population, and
they contribute to a considerable amount of morbidity worldwide (1). According to the
Global Burden of Diseases, Injuries, and Risk Factors Study, two of these illnesses,
schizophrenia and bipolar disorder, accounted for over 27 million years lived with disability
in 2010 (2). Schizophrenia has been shown to reduce the life-span of sufferers by more than
18 years because of factors such as substance use, poverty, neglect of personal well-being,
smoking, metabolic syndrome, and suicide (3, 4).

Author Manuscript

Antipsychotic drugs are the mainstay of treatment for psychosis, yet they are associated with
substantial heterogeneity in their therapeutic efficacy (5, 6). Nonresponse to standard
antipsychotic agents contributes to poor functional outcomes and a large economic impact
on health care systems, including up to a tenfold increase in total health resource utilization
(7, 8). Treatment algorithms for these illnesses are devoid of prognostic measures, and
clinicians often resort to trial and error when faced with the potential inefficacy of their
treatment choices. Moreover, when patients do not have an adequate clinical response to
treatment, they may endure prolonged periods of untreated illness. There is some evidence
that nonresponse within the first 2 weeks of treatment may ultimately predict a failed
treatment trial, yet even this approach requires costly trial and error (9, 10). Moreover, this
finding is limited to patients with chronic illness; for patients with first-episode
schizophrenia, it is recommended that antipsychotic drug trials last up to 16 weeks (11).

Author Manuscript

Current practice suggests a need for reliable, biologically based prognostic measures of
treatment response to antipsychotic agents. In the domain of neuroimaging, structural
methods have shown that differences in cortical thickness, asymmetry, and gyrification may
be associated with subsequent response to antipsychotic treatment (12, 13). Reduced white
matter integrity has also been linked to nonresponse to treatment in patients with firstepisode psychosis (14). One recent study demonstrated that functional connectivity of the
ventral tegmental area is associated with treatment response (15). Although important in
explicating pathophysiological mechanisms, these findings have not been replicated in
independent cohorts and have not resulted in predictive tests with clinical utility.

Author Manuscript

Multiple lines of evidence suggest that variation in the physiology of the striatum may be
critical to antipsychotic treatment outcomes. This subcortical region contains a dense
concentration of dopamine D2 receptors, the shared target of all known antipsychotic agents.
While genetic variation at the dopamine D2 receptor has replicably been shown to influence
response to these medications, the modest size of this effect limits its clinical utility (16).
Treatment-resistant schizophrenia has been associated with normal dopaminergic synthesis
capacity in the striatum, while treatment responders demonstrate elevated striatal dopamine
in psychotic illness (17, 18). In congruence with cross-sectional data that has linked
abnormal corticostriatal interactions with psychotic illness (19, 20), we recently reported
that improvement of psychotic symptoms is associated with changes in striatal functional
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connectivity over the course of treatment (21). In light of these findings, we hypothesized
that alterations in functional connectivity of the striatum may provide prognostic value in the
treatment of psychosis.
Our aim in this study was to develop and test a prognostic biomarker, based on functional
connectivity of the striatum, with the potential for clinical utility in the prediction of positive
symptom response to antipsychotic treatment. We identified the putative biomarker in a
discovery cohort of patients with first-episode schizophrenia, and then tested the results in a
generalizability cohort of patients with chronic psychotic illness who were newly
hospitalized for an acute psychotic episode.

Method
Author Manuscript

We developed and tested the putative biomarker in a stepwise manner, which we outline
here, with further details provided in the sections below. As shown in Figure 1, we identified
targets of striatal functional connectivity that predicted response in a discovery cohort of
patients undergoing controlled treatment for their first episode of schizophrenia. First, we
placed seeds in predefined regions of interest within the striatum. Next, we obtained wholebrain resting-state correlation maps of the time series derived from these regions of interest.
Striatal connectivity values from each voxel were then entered into Cox regression analyses
to predict treatment response in the discovery cohort. Voxels that were significant in the Cox
regression were then identified, and their striatal connectivity values were summed and
weighted based on an independent cohort of healthy volunteers, in order to reduce
overfitting. This weighted sum is a scalar value called the striatal connectivity index, and the
constituent connections of interest identified from our discovery cohort can then be directly
applied to any subsequent scans. Thus, in the present study, the striatal connectivity index
was obtained in the generalizability cohort, by placing striatal seeds and obtaining their
resting-state correlation maps. The key regions that predicted response in the discovery
cohort were then directly selected on the generalizability cohort patients' scans, and the
connectivity values of these regions were weighted (based on the same cohort of healthy
volunteers mentioned above) and summed to form the striatal connectivity index for each
participant in the generalizability cohort. These striatal connectivity index values were then
compared with observed treatment response and hospital length of stay for the patients in the
generalizability cohort.

Author Manuscript
Participants

Author Manuscript

The discovery cohort consisted of 41 patients between the ages of 15 and 40 who were
experiencing their first episode of a schizophrenia spectrum disorder (schizophrenia,
schizophreniform disorder, schizoaffective disorder, or psychotic disorder not otherwise
specified) and had no more than 2 weeks of cumulative lifetime exposure to antipsychotic
medication. Patients underwent resting-state functional MRI (fMRI) scanning and symptom
ratings before being assigned to double-blind randomized controlled treatment with either
risperidone or aripiprazole for 52 weeks (see NCT00320671 at ClinicalTrials.gov). This
analysis includes data only from the first 12 weeks of treatment, the acute treatment trial.
Assessments with the Clinical Global Impressions Scale (CGI) and the Brief Psychiatric
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Rating Scale–Anchored Version (BPRS-A) were performed weekly during the first 4 weeks,
then biweekly for the remaining 8 weeks of the acute treatment trial. Based on our previous
work in first-episode patients (22), treatment response was defined a priori as two
consecutive visits with a CGI improvement score of 1 or 2 (much or very much improved)
and a rating of 3 (mild)or less on all of the following items of the BPRS-A: conceptual
disorganization, grandiosity, hallucinatory behavior, and unusual thought content.

Author Manuscript
Author Manuscript

The generalizability cohort consisted of 40 patients hospitalized at the Zucker Hillside
Hospital for acute psychotic symptoms. Patients had diagnoses of schizophrenia,
schizophreniform disorder, schizoaffective disorder, psychotic disorder not otherwise
specified, or bipolar I disorder with psychotic features. The clinical management of these
patients followed routine clinical guidelines and was not influenced by our research protocol
but in all cases included antipsychotic medication. Patients were approached for
participation in the study shortly after being admitted to the hospital. They underwent
resting-state fMRI scanning and evaluation of symptoms with the BPRS-A at baseline and
weekly during hospitalization until discharge or treatment response. Treatment response in
this group was defined in the same way as it was in our first-episode schizophrenia group.
However, absolute response criteria differed between our first-episode schizophrenia and
generalizability cohorts because of the nature of the study designs. Patients in the former
were evaluated in the context of a large clinical trial that allowed for frequent clinical
ratings, while in the latter, patients were evaluated only during their hospitalization, the
duration of which was determined by their clinicians and was usually less than 4 weeks. Our
primary measure of treatment response in the generalizability cohort, a 20% reduction in
severity ratings on core psychotic symptoms, was required to occur within the first 2 weeks
of treatment, based on evidence from previous research that nonresponse within the first 2
weeks of treatment may ultimately predict a failed treatment trial (9, 10). Length of hospital
stay was used as a secondary measure of response.
The healthy volunteer sample consisted of 41 participants, with an age and gender
distribution nearly identical to that of our first-episode schizophrenia cohort. It is important
to emphasize that our hypotheses did not rely on direct comparison between first-episode
schizophrenia patients and healthy volunteers. We used this healthy volunteer group for a
more unbiased construction of weightings for our striatal connectivity index calculation, in
order to minimize overfitting in the discovery cohort.

Author Manuscript

All participants received a complete description of the study and provided written informed
consent according to a protocol that was approved by the Institutional Review Board of the
North Shore-Long Island Jewish Health System. Additional methodological details have
been published elsewhere (21) and are included in the data supplement that accompanies the
online edition of this article.
Resting-State fMRI Image Acquisition and Preprocessing
Resting-state fMRI scans were collected on a GE3-T scanner. Five-minute resting-state
functional scans (150 whole-brain volumes) were acquired for each study participant.
During the scan, participants were asked to close their eyes and were instructed not to think
of anything in particular. The acquisition parameters and preprocessing methods are
Am J Psychiatry. Author manuscript; available in PMC 2017 January 01.
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described in the data supplement; notably, strict attention was paid to potential motion
artifacts according to the methods described by Power et al. (23).
Functional Connectivity Analyses

Author Manuscript

As mentioned earlier, our aim was to develop a potential biomarker of treatment response
based on intrinsic functional connectivity between striatal subregions and the rest of the
brain. To generate this index, a seed-based functional connectivity approach was applied to
the striatum based on the methods of Di Martino et al. (24), which we previously adopted
(21). Using these methods, we created 3.5-mm spherical regions of interest, bilaterally, in
the dorsal caudate, ventral caudate, nucleus accumbens, dorsal rostral putamen, dorsal
caudal putamen, and ventral rostral putamen (see Table S1 and Figure S1 in the online data
supplement). Once regions of interest were defined, the mean time course of resting-state
blood-oxygen-level-dependent activity was extracted from each seed region. Whole-brain
voxel-wise correlation maps for each region of interest were then created with the extracted
waveform as a reference. The Fisher z-transformation was applied to the resulting
correlation maps. Striatal connectivity maps for each striatal region of interest showed good
correspondence with previous studies that utilized this method (21, 24).
Voxel-Wise Survival Analysis

Author Manuscript

These striatal connectivity z maps were then utilized to develop the putative biomarker as
follows: 1) for every voxel located within gray matter (181,144 voxels total), the
corresponding connectivity strength for each first-episode patient was entered into a
univariate Cox regression analysis along with clinical outcome (response or nonresponse)
and time to outcome or study dropout (in weeks);2)the resulting z scores of this analysis for
each voxel were placed in Montreal Neurological Institute standard brain space to create
whole-brain maps; and 3) at the group level, we performed one-sample t tests on these maps
for each region of interest. While it is common in case-control studies of psychiatric
disorders to apply Bonferroni-style corrections to functional neuroimaging data, the aims of
our study dictated a different statistical approach. As our goal was to capture the maximal
amount of treatment-related variance for our potential biomarker, we applied a threshold of
p<0.005 to our analysis of the discovery data set. Once the significant elements (connections
of interest) were identified and a striatal connectivity index was developed from these
elements, our use of a fully independent generalizability cohort allowed for an unbiased
estimate of the prognostic value. In the discovery cohort, a total of 91 functional connections
across the 12 input regions of interest predicted treatment response in either a positive or a
negative direction (Figure 2; see also Tables S2 and S3 in the online data supplement).

Author Manuscript

Striatal Connectivity Index Calculation
Next, a striatal connectivity index was computed using data from the 91 predictive striatal
functional connections. In order to reduce circularity and minimize overfitting in this
computation, we normalized data from the discovery cohort of first-episode schizophrenia
patients with data from healthy participants. To do this, we extracted the raw correlational
values of all 91 predictive striatal functional connections from connectivity maps of all
participants in our healthy volunteer group as well as in our first-episode schizophrenia
cohort. The mean and standard deviation were calculated on correlational values at each of
Am J Psychiatry. Author manuscript; available in PMC 2017 January 01.
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the 91 functional connections from the healthy volunteer group and used to z-transform the
patient data. A principal-components analysis was performed on the extracted functional
correlational values in the healthy volunteer data set. The first principal component was
computed. Loadings onto this first principal component across all 91 functional connections
were applied to connectivity values in the first-episode cohort. Similarly, loadings onto that
first principal component in the healthy volunteers were also applied to the raw connectivity
values in the generalizability cohort. The sum of the products of all correlational values and
loadings onto the first principal component was calculated for each patient. We called this
value a striatal connectivity index, which represents the expression of the first principal
component of striatal connections of interest from the healthy volunteer cohort.

Author Manuscript

This index was examined for prognostic value against the predetermined response/
nonresponse designation. A cutoff threshold for this striatal connectivity index was derived
based on responder/nonresponder status in the discovery cohort, and the sensitivity and
specificity of this threshold were tested in the generalizability cohort to determine clinical
utility. The ability of the striatal connectivity index to predict length of stay was also
examined in the generalizability cohort.

Results

Author Manuscript

Forty-one patients with first-episode schizophrenia were included in the discovery cohort.
Of this group, 24 patients were classified as responders (58%) and 17 as nonresponders
(Table 1), consistent with previous findings (22, 25). The healthy volunteer group that was
used for normalization of the striatal connectivity index calculation included 41 participants
who had the same mean age (21 years, SD=5.1) and gender distribution (29 males,12
females)as the first-episode schizophrenia group. The generalizability cohort consisted of 40
participants treated with antipsychotic drugs (Table 1; treatment details are provided in the
online data supplement). Twenty of these patients were classified as responders and 20 as
nonresponders.
Whole-Brain Predictors

Author Manuscript

We utilized voxel-wise Cox regressions to search for treatment response predictors in striatal
connectivity values across the whole brain. We identified 91 connections that were
significantly associated with treatment response (see Tables S2 and S3 in the data
supplement). The insular cortex, opercular cortex, anterior cingulate, thalamus, orbitofrontal
cortex, and posterior cingulate were regions that frequently appeared on the list of predictive
connections with the striatum. Intriguingly, there was an anterior-posterior gradient in the
directionality of the associations (Figure 2). In posterior regions, greater connectivity with
striatal subdivisions at baseline was associated with better subsequent treatment response;
we called these “positive predictors.” In more frontal regions, by contrast, we observed
prediction in the negative direction; lower striatal connectivity of these nodes at baseline was
associated with better subsequent response.
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To derive the prognostic index, combining information from all 91 connections into a single
striatal connectivity index, we normalized the raw connectivity values using the group of
healthy participants. Loadings from the first principal component of the functional
connectivity values of the 91 connections in the healthy volunteers were calculated in the
first-episode schizophrenia group. As shown in Figure 3, a connectivity index based on these
loadings was plotted against the predetermined response/nonresponse status, excluding six
subjects who dropped out of the trial within the first 2 weeks (i.e., before an adequate trial
had been attained). Not surprisingly, the test separated responders and nonresponders
(p=4×10−5), with lower indices associated with subsequent response. A cutoff value was
placed just above the highest-scoring responder (striatal connectivity index=3.8), but it
should be noted that the sensitivity and specificity of this cutoff are confounded by the fact
that this index was initially derived from analysis of this same cohort.

Author Manuscript

Replication
In order to independently replicate the association between striatal connectivity index and
outcome, and to determine the sensitivity and specificity of the cutoff threshold in a realworld clinical setting, we applied these methods to a generalizability cohort of chronic
psychosis patients undergoing antipsychotic drug treatment. The striatal connectivity index
showed a significant separation between responders and nonresponders (p=0.003). In the
associated receiver operating curve, we observed 80% sensitivity and 75% specificity for
prediction, and an area under the curve of 0.78 (Figure 3). The positive predictive value of
the index was 76%; the negative predictive value was 79%.

Author Manuscript

As a secondary analysis, we plotted the striatal connectivity index against length of stay for
the current hospitalization. The median length of stay was 24 days (range, 7–235). There
was a significant association between length of stay and striatal connectivity index (R2=0.11,
p=0.04). To assess whether extreme outliers in the length-of-stay analysis biased these
results, we recalculated all statistics after natural log transformation of the data (Figure 4).
Our results remained significant (R2=0.11, p=0.03).

Discussion

Author Manuscript

In this study, we provide evidence for a potential baseline resting-state fMRI biomarker that
predicts response to treatment with antipsychotic drugs in patients with psychotic disorders.
We identified striatal functional connectivity nodes significantly associated with treatment
response in a discovery cohort of patients with first-episode schizophrenia and developed a
prognostic striatal connectivity index normalized using a group of demographically
comparable healthy participants. We then applied this measure to a generalizability cohort of
chronic patients undergoing treatment for acute psychotic symptoms. In both the discovery
and generalizability data sets, we observed a significant separation between responders and
nonresponders, with clinically meaningful levels of sensitivity and specificity. In addition,
the prognostic index correlated with length of stay for psychotic symptoms in a large
psychiatric treatment facility.
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Our results are broadly consistent with other neuroimaging studies, across multiple
modalities, demonstrating that antipsychotic drugs modulate functional activity and
connectivity of the basal ganglia (21, 26–28). While there has been an abundance of
neuroimaging research in psychotic disorders, there remains a crucial gap between this work
and clinical practice. In particular, resting-state fMRI has provided insight into the intrinsic
functional makeup of psychotic disorders but has yet to offer clinical utility. This method has
been preliminarily examined as a prognostic measure in depression and chronic pain, as well
as in schizophrenia (15, 29, 30). Clinical assays derived from the method we describe have
the potential to tease apart the clinical heterogeneity of psychotic disorders and to guide
real-world treatment decisions.

Author Manuscript

Development of prognostic tools is required to bring contemporary “precision medicine”
approaches to psychiatry. To our knowledge, this study is the first to report a prognostic
fMRI-derived measure validated in an independent cohort of antipsychotic-treated patients.
At present, however, the striatal connectivity index we describe here is insufficient to
precisely target antipsychotic prescriptions to specific patients, for two reasons: first, all
currently available antipsychotics are mechanistically and clinically similar (with the
possible exception of clozapine), and second, the observed sensitivity (80%) and specificity
(75%) of the striatal connectivity index suggest additional room for improvement.

Author Manuscript

With these limitations in mind, however, striatal connectivity index scores may be
sufficiently accurate for more limited, but still clinically relevant, decision-making purposes.
For example, a prognostic tool could be used in hospital settings to target limited clinical
resources such as additional psychoeducation for patients and their families to reduce
frustration with potentially longer treatment trials; nonadherence to care has been shown to
be associated with increased rates of relapse and worsened outcomes for patients, and lack
of initial efficacy is a prominent cause of nonadherence (25, 31). Moreover, patients who do
not remit are more likely to exhibit violent behavior and to need emergent care (32); thus,
additional social work support could be deployed for those most likely to haves
nonadherence, relapse, and violence carry the dual burdens of additional patient suffering
and greater cost to health care delivery systems (7, 8).

Author Manuscript

Biomarkers such as the striatal connectivity index may also assist in the development of
novel treatments for patients in several ways. First, patients entering clinical trials could be
stratified on the basis of the striatal connectivity index, and noninferiority trials could be
targeted to those patients who are likely to respond to known antipsychotic agents.
Conversely, clinical trials involving agents with novel mechanisms may seek to target
patients who are likely to be nonresponders to conventional D2 antagonists. Additionally, the
circuitry identified in the present study, combined with our previous demonstration of striatal
circuits that are directly changed over time with efficacious treatment (21), can provide an
important index of “target engagement” for the development of novel therapeutics (33). Of
note, one of the prognostic connections, between the right ventral rostral putamen and the
anterior cingulate, was previously shown, in as maller subset of our first-episode
schizophrenia patients, to increase in strength as psychotic symptoms resolved (21).
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Our results also provide further insight into possible mechanisms that underlie psychotic
symptoms. Many of the striatal functional connections we observed to be significant
predictors of treatment response are located in regions that make up the salience network. It
has been theorized that the pathophysiology of psychosis is associated with abnormal
assignment of salience to external stimuli (34). Overall, we observed lower striatal
connectivity indices in responders and higher indices in nonresponders. Our results indicate
that deficits in connectivity between the striatum and regions implicated in various
functional networks, including the salience network, may be a target of antipsychotic
treatment, consistent with our previous study of treatment mechanisms (21). By contrast,
nonresponders tended to have greater striatal connectivity, suggesting an alternative
mechanism for their psychosis that is impervious to the primary functional effects of
standard antipsychotic medications. Further studies are required to understand the
neurophysiological implications of our results.

Author Manuscript

While it was not the objective of the present study, our work here opens the door to research
that would further characterize our connectivity index. It remains unknown how different
stages of psychotic illnesses—from onset to a chronic, relapsing phase—will affect
functional connections of the striatum. Similarly, future work may clarify the impact of
psychotropic medications other than antipsychotics on our connectivity index. While we find
that our striatal connectivity index correlates with length of stay in the hospital, only 11% of
the total variance is accounted for by this finding. Further work with additional cohorts will
be required to understand this finding.

Author Manuscript

Limitations of our analysis include access to a relatively limited number of patients in the
two cohorts. While we view the heterogeneity of our generalizability data set as a strength of
our approach, indicative of the potential for broad applicability, further characterization of
the striatal connectivity index in larger, well-characterized cohorts of varying illness
subtypes will be necessary before this putative biomarker can be used for clinical decision
making. Combinations of this index and other biologically based markers, such as
pharmacogenomic measures and genetic loading for illness, may enhance our results.
Finally, it will be important to determine how this index works in the context of treatment
with clozapine, which has markedly different clinical properties from all other
antipsychotics.

Author Manuscript

To summarize, we describe a potential prognostic biomarker of response to antipsychotic
medication in patients entering treatment for psychosis. With further development, the
striatal connectivity index may have clinical utility, and with subsequent integration with
clinical algorithms available to prescribers, it has the potential to decrease the overall
suffering of patients and their families, and to decrease the strain on our health care systems.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Outline of the Study's Methodological Approach
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Figure 2. Location of Striatal Functional Connections Included in the Analysisa
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aThe

figure illustrates functional connections with our striatal regions of interest that showed
predictive value and were included in the computation of our striatal connectivity index.
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Figure 3. Striatal Connectivity Index in the Discovery and Generalizability Data Sets
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Figure 4. Striatal Connectivity Index and Length of Stay in the Hospitala
ar=0.335,

p=0.034.
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Mean antipsychotic dosage (chlorpromazine equivalent in mg/day)

Psychotic symptoms

Total

137.0

3.6

400.0

14.7

0.5

8.3

4.8

Baseline Clinical Global Impressions Scale

2.5
269

44.1

140

Duration of untreated psychosis (days)

Baseline Brief Psychiatric Rating Scaleb

12.3

Education (years)

SD

Mean
3.8

66

N

16

%

21.2

N

Responders (N=24)

396.3

13.1

43.0

4.6

110

12.3

21.9

Mean

13

%

553.5

11.7

19.9

13.7

28.5

Mean

15

%

250.0

3.4

5.5

2.3

11.0

SD

75

N

Responders (N=20)

715.4

12.1

16.9

13.0

28.0

Mean

13

%

281.0

4.1

5.7

1.3

9.7

SD

65

Nonresponders (N=20)

Generalizability Cohort

BPRS=Brief Psychiatric Rating Scale. The seven-item version was used for the generalizability cohort, and the 18-item version for the first-episode schizophrenia group.

b

200.0

3.2

8.2

0.7

113

2.0

5.9

SD

77

N

Nonresponders (N=17)

First-Episode Schizophrenia Cohort

Age (years)

Male

Characteristic

No significant differences on any measure between responders and nonresponders within each cohort.

a
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